32.jpg)
56.jpg)
Protein kinase inhibitors
WO2017033019 (A1)
The CNIO has developed compounds useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. The Experimental Therapeutics Programme from the CNIO has developed novel pharmaceutically-useful compounds, useful as kinase inhibitors (such as inhibitors of the CDK8 and/or Haspin kinases). The compounds are of potential utility in the treatment of diseases such as cancer, particularly colorectal/colon cancer, breast cancer, pancreatic cancer and cervical cancer.
The compounds of the present invention provide selective targeted therapies which provide advantages over current anti-cancer treatments, for example by reducing side effects (e.g. by preventing the killing of normal cells, as may occur using e.g. chemotherapy).